Biogen Inc. (SNSE:BIIB)

Market Cap	24.89T +20.9%
Revenue (ttm)	8.91T +2.2%
Net Income	1.16T -20.8%
EPS	7,917.77 -21.4%
Shares Out	n/a
PE Ratio	21.37
Forward PE	12.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	n/a
Previous Close	181.06
Day's Range	n/a
52-Week Range	120.74 - 245.00
Beta	n/a
RSI	99.96
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,500
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: BIIB

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD